1. Report Prologue
2.2 Scope of the Study
2.2.1 Research Objective
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Upcoming trends
5.7.1 Market trends
5.7.2 Technological trends
5.7.3 Insurance & Regulations
6. Global Chondrosarcoma Market by Types
6.1 Conventional chondrosarcoma
6.2 Clear cell chondrosarcoma
6.3 Myxoid chondrosarcoma
6.4 Mesenchymal chondrosarcoma
6.5 Dedifferentiated chondrosarcoma
7. Global Chondrosarcoma Market by Diagnosis
7.1.1 Open Biopsy
7.1.2 Core Needle Biopsy
7.2.2. Computed tomography scan (CT scan)
7.2.3 Magnetic resonance imaging (MRI)
7.2.4 Positron emission tomography (PET) scan
7.3.1 Cinacalcet (Sensipar)
7.3.2 Sodium thiosulfate
7.5 Adequate Pain Control
7.6.1 Low-dose tissue plasminogen activator (TPA)
7.7 Others8. Global Chondrosarcoma Market by Treatment
8.2.1 Physical therapy
8.2.2 Radiation therapy
8.3.1 External hemipelvectom
8.3.2 Internal hemipelvectomy
9. Global Chondrosarcoma Market by End User
9.1 Hospitals and clinics
9.2 Medical Research centers
9.3 Academic institutes
10. Global Chondrosarcoma Market by Region
10.2.1 North America
10.2.1.1 The US
10.2.2 South America
10.3.1 Western Europe
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4.4 South Korea
10.4.5 Rest of Asia
10.6 Middle East and Africa
10.6.2 Saudi Arabia
10.6.4 Rest of Middle East and Africa
11. Competitive landscape
12. Company profile
13.1 Key findings
13.1.1 From CEO’s viewpoint
13.1.2 Unmet needs of the market
13.2 Key companies to watch
13.3 Prediction of Chondrosarcoma Market
Market Synopsis of Global Chondrosarcoma Market:
Chondrosarcoma is a rare type of bone cancer that consist predominantly of cartilage. It mostly affect pelvis, upper arms (humerus), thighs (femur), ribs, and shoulder blades (scapula) and is the most common in people older than 40 years.
Rising funding for R&D and clinical trials as well as FDA approvals are major driving forces for global chondrosarcoma market. Major players are funding large amount of money in new product development for effective cure that is another key driver for the market.
The Global Chondrosarcoma market is growing at the CAGR of ~3.1% during the forecast period and expected to reach US$ 537.8 million by 2023.
Study objectives of Global Chondrosarcoma Market:
FIGURE 1 GLOBAL CHONDROSARCOMA MARKET SHARE BY TYPES, 2016 (%)
Sources: National Center for Biotechnology Information, National Kidney Foundation, Inc., CheckOrphan, Directorate of Industries, Annual report, White paper, Company Presentation
Global chondrosarcoma market has been segmented on the basis of types which comprises of conventional chondrosarcoma, clear cell chondrosarcoma, myxoid chondrosarcoma, mesenchymal chondrosarcoma, de-differentiated chondrosarcoma.
On the basis of diagnosis, it is segmented into biopsy, imaging, and others. Biopsy is further sub-segmented into shave open biopsy, core needle biopsy, and others. Imaging is further sub-segmented into X-Ray, Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan, and others.
On the basis of treatment, the market has been segmented into intensive surgery, therapies, hemipelvectomy, and others. Therapies are further sub-segmented into physical therapy, radiation therapy, chemotherapy, and others. Hemipelvectomy is further sub-segmented into external hemipelvectomy, internal hemipelvectomy, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Regional Analysis of Global Chondrosarcoma Market:
Considering the global scenario of the market, North America holds the largest market share owing to various factors such as increasing prevalence of chondrosarcoma and increasing investment in R&D. Europe is the second largest market due to advanced healthcare facilities where the countries like Germany and UK are holding the largest market share. New cases of chondrosarcoma are rising in Asia Pacific region. Additionally, improving healthcare infrastructure and rising healthcare expenditure are driving the growth for Asia Pacific chondrosarcoma market. Due to low knowledge of disease and treatment, Middle East and Africa (ME&A) is likely to have a limited growth in the market.
Key Players for Global Chondrosarcoma Market:
Some of the key players in this market are: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others The report for Global Chondrosarcoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
Frequently Asked Questions (FAQ) :
Chondrosarcoma market is valued at USD 537.8 million by 2023.
Chondrosarcoma market can expand at 3.1% CAGR from 2017 to 2023.
Chondrosarcoma market is driven by increased funding for research and development for chondrosarcoma and rapid approvals of drugs by regulatory bodies.
North America can dominate the global chondrosarcoma market till 2023 owing to increasing number of cases of the disease.
Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., and Novartis AG, and others are notable players of the global chondrosarcoma market.